Based on these findings, strategies to ameliorate the inflammatory pathology during respiratory infection such as COVID‐19 are now designed to target STING rather than the downstream NLRP3 for more health benefits. This evidence concerns the gene NLRP3 and respiratory tract infectious disorder.